October opens with US equities holding near record levels after months of consolidation, while borrowing costs are moving against growth investors. The S&P 500 finished September at 7,651.54, the Federal Reserve raised its policy rate for the first time in three years on September 16, and the 10-year Treasury yield touched 5% in mid-September before retreating at the start of October. Against that backdrop, the five stocks below, Microsoft, Amazon, Alphabet, Eli Lilly and Vertiv, share a common profile: double-digit revenue growth, large contracted backlogs and the financial capacity to fund expansion without depending on cheap credit. This guide explains why each stock made the list, what valuation looks like at current prices and which risks could break the thesis.
The October 2026 Market Backdrop
Three forces define the setup for long-term investors this month.
The first is monetary policy. The Fed lifted the federal funds target range by a quarter point to 3.75%-4.00% in a unanimous vote, its first increase since July 2023. Sixteen of 18 officials expect at least one more hike this year, and Chair Kevin Warsh made clear that inflation remains the priority. Higher discount rates weigh most on long-duration growth stocks, which raises the importance of earnings quality and cash generation.
The second is the earnings calendar. Third-quarter reporting opens on October 8 with PepsiCo, and the large banks follow on October 13 and 14. FactSet projects S&P 500 earnings growth near 29% for the quarter, although the gains are concentrated in a small group of companies. Alphabet and Microsoft are expected to report on October 28, and Amazon and Eli Lilly on October 29 (dates unconfirmed at the time of writing). The Fed meets on October 27-28, so policy and earnings news will arrive in the same week.
The third is seasonality. Over the past 50 years the S&P 500 has averaged a 0.7% gain in October and finished the month higher 58% of the time, yet October is also the most volatile month on a 95-year view. The so-called October effect describes volatility, not a reliable decline.
How These Five Stocks Were Selected
A list of stocks to buy in October is only useful if the screening logic is transparent. Each company below was evaluated on the same six criteria, which also work as a checklist for evaluating long-term growth stocks in any rate environment:
- Revenue acceleration: growth that is speeding up or holding at a high level, not fading.
- Backlog visibility: contracted or ordered demand that supports revenue for several quarters.
- Margins and cash flow: operating profit that scales with revenue and cash generation that can fund investment.
- Balance-sheet capacity: the ability to absorb higher interest rates and heavy capital spending.
- Valuation relative to growth: a price that leaves room for error, judged against peers and analyst targets.
- Distinct risk drivers: a basket whose holdings do not all depend on the same single outcome.
The last criterion matters because four of the five picks are tied, directly or indirectly, to artificial intelligence spending. Eli Lilly is included partly as a diversifier, since its growth depends on obesity and diabetes medicine rather than on data center demand.
The Top 5 Stocks to Buy in October 2026 at a Glance
- Microsoft (MSFT): the cloud and AI software leader with accelerating Azure growth and positive free cash flow.
- Amazon (AMZN): AWS growth at its fastest pace in 18 quarters, paired with a heavy spending cycle.
- Alphabet (GOOGL): Google Cloud growing above 80% with a backlog above $500 billion and a valuation below most mega-cap peers.
- Eli Lilly (LLY): the obesity and diabetes market leader with a deep late-stage pipeline.
- Vertiv (VRT): the power and cooling supplier behind AI data center construction, trading well below its recent highs.
1. Microsoft (MSFT): Azure Momentum at a Reasonable Multiple
Why Microsoft Ranks First
Microsoft closed fiscal 2026 with revenue above $331 billion, up 18%, and operating income up 21% to more than $155 billion. In the June quarter, revenue reached $90.0 billion, and Azure growth accelerated to 43% from about 40% in the prior quarter. Azure revenue passed $100 billion for a full fiscal year for the first time. Management guided to roughly 45% Azure growth in constant currency for the September quarter and said customer demand continues to exceed available capacity. Microsoft 365 Copilot reached more than 30 million paid seats, up from 20 million in April, which shows the AI software layer is beginning to monetize alongside the cloud infrastructure layer.
Valuation Snapshot
The shares trade near $515, giving Microsoft a market value of about $3.8 trillion. On trailing earnings of roughly $17.95 per share, the trailing price-to-earnings ratio is close to 29. The consensus analyst target sits near $578, about 12% above the current price, and 52 of 55 covering analysts rate the stock Buy or Strong Buy. The 52-week range runs from $349.20 to $553.72, so the stock remains below its high despite the earnings acceleration. The dividend yield is about 0.76%, which makes this a growth holding rather than an income holding.
Risks to Monitor
Gross margin was 67% in the June quarter, down from a year earlier, as infrastructure costs rise. Reported earnings are also influenced by Microsoft’s investments in AI model developers, including a $3.2 billion gain on its Anthropic stake in the June quarter, so investors should track operating income rather than headline earnings per share. Management said Microsoft should remain cash-flow positive in fiscal 2027, but capital spending is set to rise. The next test is the fiscal first-quarter report, expected around October 28, and the Ignite conference in November, where Wells Fargo expects clearer Azure disclosures.
2. Amazon (AMZN): AWS Re-Acceleration and a Heavy Investment Cycle
Why Amazon Makes the List
Amazon’s second-quarter revenue reached $200.6 billion, up 20%, and operating income rose 43% to $27.5 billion. Amazon Web Services grew 36.7% to $42.2 billion, its fastest rate in 18 quarters and the fifth consecutive quarter of acceleration, at an operating margin of 39.4%. AWS backlog stands at $496 billion, and management said its AI and custom chip businesses each exceeded a $25 billion annual run rate. The pattern is notable for a business of this size: growth is speeding up as the base gets larger.
Valuation Snapshot
Amazon closed September at $249.15, roughly 8% below the $271.58 reached the day after the July earnings release, and its market value is about $2.7 trillion. The consensus target from 59 analysts is near $330, with a range from $230 to $405. The trailing price-to-earnings ratio of about 20 looks low, but second-quarter net income included a $53.4 billion non-operating gain tied to Amazon’s investments in Anthropic, so that multiple understates the true price investors are paying for operating earnings. Operating income and AWS margins are the cleaner measures.
Risks to Monitor
Amazon raised its 2026 cash capital expenditure plan to about $220 billion from $200 billion, citing higher memory costs, and trailing free cash flow turned negative at about $7.6 billion. CEO Andy Jassy has said free cash flow will face headwinds until new data centers come online. The investment case therefore depends on AWS converting its backlog into revenue on schedule. Third-quarter results are expected on October 29, and any change in the capex plan or AWS growth rate will move the shares.
3. Alphabet (GOOGL): Cloud Backlog and a Discount to Its Peers
Why Alphabet Is on the List
Alphabet reported second-quarter revenue of $119.8 billion, up 24%, with operating income up 30% to $40.8 billion at a 34% margin. Google Cloud revenue jumped 82% to $24.8 billion, and Cloud backlog reached $514 billion, up more than $50 billion in one quarter. Search and other advertising revenue still grew 17%, which addresses the long-running concern that AI products would erode the search franchise. The Gemini app now has 950 million monthly active users, and nearly 90% of the Fortune 100 use Gemini Enterprise. Morgan Stanley estimates that external sales of Google’s custom TPU chips could generate about $84 billion of Cloud revenue in 2027, an analyst projection that remains unproven.
Valuation Snapshot
The stock trades near $343, about 16% below its 52-week high of $408.61. Trailing earnings of $9.11 per share in the second quarter were inflated by $98.0 billion in unrealized gains on equity holdings, so the trailing multiple near 17 is not a reliable guide. A forward multiple near 25.7 is more representative and sits below the multiples of several mega-cap peers despite faster growth. The consensus target is about $429, roughly 25% above the price, and 59 of 63 analysts rate the stock a Buy with none recommending a sale.
Risks to Monitor
Capital spending is the main variable. Alphabet raised its 2026 capex guidance to $195-$205 billion and said 2027 spending will increase significantly, and second-quarter free cash flow was negative at $5.9 billion. The company also announced equity offerings of up to $80 billion in June, including a $40 billion at-the-market program expected to begin in the third quarter, which creates dilution and supply of new shares. Regulatory fines, delays in flagship Gemini model releases and a 21% drawdown between mid-May and late July show that the shares can fall sharply. Third-quarter results are expected on October 28.
4. Eli Lilly (LLY): Obesity and Diabetes Leadership Outside the AI Trade
Why Eli Lilly Belongs in the Basket
Lilly delivered second-quarter revenue of $23.0 billion, up 48%, driven by a 60% increase in volume for Mounjaro and Zepbound, partly offset by a 13% decline in realized prices. International revenue grew 80% to $8.6 billion, and US revenue rose 33% to $14.4 billion. Management raised 2026 revenue guidance to $85-$87 billion and non-GAAP earnings guidance to $35.50-$36.50 per share, a range that absorbs $3.03 per share of acquired research charges from second-quarter deals.
The pipeline supports the growth case beyond 2026. Foundayo (orforglipron), the company’s oral GLP-1, has been approved by the FDA for obesity, with a US submission for type 2 diabetes filed. In the TRIUMPH-2 trial presented in late September, patients with obesity and type 2 diabetes on the highest dose of the triple agonist retatrutide lost an average of 20.8% of body weight over 80 weeks, and Lilly plans a US filing for retatrutide in the first quarter of 2027. An investment community meeting is scheduled for December 7.
Valuation Snapshot
The stock trades around $1,150 for a market value near $1 trillion. Dividing that price by the midpoint of 2026 non-GAAP guidance gives about 32 times current-year earnings, a premium multiple that partly reflects the acquired research charges. The average analyst target is about $1,329, with individual targets ranging from $930 to $1,600, and JPMorgan raised its target to $1,500 on September 28. The stock’s five-year beta is about 0.5, far below the technology holdings on this list, which is why it works as a diversifier.
Risks to Monitor
Falling net prices are the central risk. Volume growth of 60% against a 13% price decline shows that US pricing pressure is real, and the thesis requires volume to keep outrunning price cuts. Revenue concentration in a single drug class, the timing of retatrutide approval and competitive oral GLP-1 launches are additional variables. Third-quarter results are expected before the market opens on October 29.
5. Vertiv (VRT): The Power and Cooling Supplier Behind AI Data Centers
Why Vertiv Is Included
Vertiv supplies the power distribution and liquid cooling systems that must be installed before AI servers can run. Second-quarter sales rose 24.1% to $3.27 billion, with operating margin of 19.5%, up from 16.8% a year earlier, and a free cash flow margin of 28.3%. Adjusted earnings per share were $1.52, ahead of the $1.43 consensus. Revenue missed estimates of about $3.38 billion, and the stock fell by double digits after the report, which management attributed to timing shifts from supply chain congestion and multi-phase projects rather than weaker demand. The third-quarter outlook calls for sales of $3.65-$3.85 billion and adjusted earnings of $1.77-$1.83 per share. Backlog exceeded $15 billion at the first-quarter report, covering roughly 12 to 18 months of revenue.
Valuation Snapshot
Shares trade near $250 for a market value of about $97 billion, well below the levels reached before the July report. The trailing price-to-earnings ratio is about 56. The average analyst target is about $338, with a range from $236 to $427, and Wells Fargo initiated coverage at Overweight with a $340 target in late September. Earlier in 2026, one published peer comparison placed Schneider Electric near 28 times forward earnings and Eaton near 30 times, so Vertiv’s multiple carries a clear growth premium.
Risks to Monitor
Vertiv is the highest-risk stock on this list. Its five-year beta is about 2.1, nearly double that of Microsoft. Demand depends on hyperscaler capital spending, and analysts have noted that a large share of planned US data center projects have faced delays or cancellations, mainly because of power shortages. Europe was weak in the first quarter, with organic sales in EMEA down 29%, while the Americas grew 44%. Third-quarter results are expected in late October, with the exact date unconfirmed. Position size should reflect the volatility.
How to Combine the Five Stocks in a Portfolio
A list of stocks is not a portfolio. Four of the five holdings, Microsoft, Amazon, Alphabet and Vertiv, would be hurt by a sharp cut in hyperscaler capital spending, even though they sit in different parts of the AI value chain. Eli Lilly provides exposure to a different growth driver, and its low beta can cushion drawdowns in technology. Investors who hold these shares through a broad index fund already own much of the AI exposure, so overlap deserves a check before adding more.
Three practical points follow from the October calendar. First, the cluster of earnings on October 28 and 29 and the Fed meeting on October 27-28 can produce large single-day moves, so staged purchases across several weeks reduce the risk of buying immediately before a surprise. Second, rising rates compress multiples on the highest-valuation names first, which argues for smaller positions in Vertiv and Eli Lilly relative to Microsoft and Alphabet. Third, long-term holders should anchor decisions to backlog conversion, margins and free cash flow, not to month-to-month price targets, which change frequently.
Frequently Asked Questions
Is October a good month to buy stocks?
Historically, October has been an average month for returns and an above-average month for volatility. The S&P 500 has gained 0.7% on average and risen in 58% of Octobers over 50 years. Long-term investors who are buying for a multi-year horizon often treat volatility as an entry opportunity, but timing a single month is unreliable.
Which stocks are best to buy when interest rates are rising?
Companies with strong free cash flow, pricing power and low debt tend to hold up better than businesses that depend on external financing. Among the five stocks here, Microsoft stands out for cash generation, while Amazon and Alphabet are currently spending more than they generate in some quarters and rely on their large cash positions and market access.
Are AI stocks overvalued in 2026?
Valuations vary widely. Microsoft trades near 29 times trailing earnings and Alphabet near 26 times forward earnings, while Vertiv trades near 56 times trailing earnings. Heavy capital spending by all three cloud leaders is the main reason valuation debates persist, because the payoff depends on backlog turning into revenue. The backlogs reported for 2026, $496 billion at AWS and $514 billion at Google Cloud, support the demand side of that argument.
Bottom Line
The five stocks combine accelerating cloud growth, a leading position in obesity medicine and an infrastructure supplier with a large backlog. Microsoft and Alphabet offer the most favorable balance of growth and valuation, Amazon offers the clearest AWS acceleration at the cost of near-term free cash flow, Eli Lilly adds diversification away from technology, and Vertiv offers the highest potential return with the highest volatility. Investors should check each thesis against the late-October earnings reports before sizing positions.
Data notes: Figures come from company earnings releases and filings for the latest reported quarters (Microsoft fiscal fourth quarter, Amazon, Alphabet, Eli Lilly and Vertiv second quarter 2026), plus market data and analyst consensus from Yahoo Finance, S&P Global and other providers as of October 1-2, 2026. Forward multiples differ by provider and adjustment method.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Stock prices change continuously, analyst targets are opinions, and past performance does not guarantee future results. Investing involves risk, including the loss of principal. Readers should conduct their own research or consult a licensed financial adviser before making investment decisions.